{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:39Z","timestamp":1789398339088,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03582-8","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:28:54Z","timestamp":1776497334000},"page":"2930-2948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa A.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Avetisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"3","key":"3582_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337. https:\/\/doi.org\/10.1007\/s12016-016-8548-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"3582_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ. Increased risk of cutaneous and systemic infections in atopic dermatitis\u2014a cohort study. J Investig Dermatol. 2017;137(6):1375\u20137. https:\/\/doi.org\/10.1016\/j.jid.2017.01.030.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"3582_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","volume":"120","author":"S Narla","year":"2018","unstructured":"Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66\u201372. https:\/\/doi.org\/10.1016\/j.anai.2017.10.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3582_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2018.11.028","volume":"80","author":"L Serrano","year":"2019","unstructured":"Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(4):904\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.028.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3582_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2020.07.111","volume":"84","author":"C Droitcourt","year":"2021","unstructured":"Droitcourt C, Vittrup I, Kerbrat S, Egeberg A, Thyssen JP. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study. J Am Acad Dermatol. 2021;84(2):290\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.111.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3582_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaip.2023.02.005","volume":"11","author":"EH van den Bogaard","year":"2023","unstructured":"van den Bogaard EH, Elias PM, Goleva E, et al. Targeting skin barrier function in atopic dermatitis. J Allergy Clin Immunol Pract. 2023;11(5):1335\u201346. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3582_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaad.2024.11.079","volume":"92","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Goleva E, Berdyshev E, et al. Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD). J Am Acad Dermatol. 2025;92(5):1132\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.079.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3582_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/pde.12665","volume":"32","author":"D Patel","year":"2015","unstructured":"Patel D, Jahnke MN. Serious complications from Staphylococcal aureus in atopic dermatitis. Pediatr Dermatol. 2015;32(6):792\u20136. https:\/\/doi.org\/10.1111\/pde.12665.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"3582_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 9. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3582_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerich K, de Bruin\u2010Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768\u201375. https:\/\/doi.org\/10.1111\/bjd.15928.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3582_CR11","first-page":"5","volume":"23","author":"A Cinats","year":"2018","unstructured":"Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Ther Lett. 2018;23(3):5\u20139.","journal-title":"Skin Ther Lett"},{"issue":"4","key":"3582_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.074.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3582_CR13","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.20674","volume":"39","author":"LF van der Gang","year":"2025","unstructured":"van der Gang LF, Atash K, Zuithoff NPA, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol. 2025;39(12):2056\u201368. https:\/\/doi.org\/10.1111\/jdv.20674.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3582_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3582_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"issue":"24","key":"3582_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"10086","key":"3582_CR17","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"1","key":"3582_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"3582_CR19","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3582_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443\u201356. https:\/\/doi.org\/10.1007\/s40257-019-00445-7.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"3582_CR21","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jaip.2023.04.052","volume":"11","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, De Benedetto A, Boguniewicz M, et al. Phenotypic and endotypic determinants of atopic dermatitis severity from the Atopic Dermatitis Research Network (ADRN) Registry. J Allergy Clin Immunol Pract. 2023;11(8):2504\u201315. https:\/\/doi.org\/10.1016\/j.jaip.2023.04.052.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3582_CR22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","volume":"152","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Schlievert PM, Yoshida T, et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023;152(5):1179\u201395. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3582_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","volume":"140","author":"C Callewaert","year":"2020","unstructured":"Callewaert C, Nakatsuji T, Knight R, et al. IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Investig Dermatol. 2020;140(1):191-202.e7. https:\/\/doi.org\/10.1016\/j.jid.2019.05.024.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"3582_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408. https:\/\/doi.org\/10.1007\/s40257-022-00685-0.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"3582_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3582_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12325-022-02322-y","volume":"40","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4\u00a0years with dupilumab. Adv Ther. 2023;40(1):367\u201380. https:\/\/doi.org\/10.1007\/s12325-022-02322-y.","journal-title":"Adv Ther"},{"issue":"2","key":"3582_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"key":"3582_CR28","unstructured":"DUPIXENT (dupilumab). Highlights of prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 26 Nov 2025."},{"key":"3582_CR29","unstructured":"DUPIXENT (dupilumab). Summary of product characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 26 Nov 2025."},{"issue":"1","key":"3582_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2421429","volume":"35","author":"H Zirpel","year":"2024","unstructured":"Zirpel H, Ludwig RJ, Olbrich H, Kridin K, St\u00e4nder S, Tha\u00e7i D. Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network. J Dermatol Treat. 2024;35(1):2421429. https:\/\/doi.org\/10.1080\/09546634.2024.2421429.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"3582_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2024.09.046","volume":"92","author":"AS Paller","year":"2025","unstructured":"Paller AS, de Bruin-Weller M, Marcoux D, et al. Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. J Am Acad Dermatol. 2025;92(2):242\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.046.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3582_CR32","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/all.16265","volume":"79","author":"SYC Tsai","year":"2024","unstructured":"Tsai SYC, Gaffin JM, Hawryluk EB, et al. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study. Allergy. 2024;79(10):2748\u201358. https:\/\/doi.org\/10.1111\/all.16265.","journal-title":"Allergy"},{"issue":"5","key":"3582_CR33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","volume":"154","author":"SYC Tsai","year":"2024","unstructured":"Tsai SYC, Phipatanakul W, Hawryluk EB, Oyoshi MK, Schneider LC, Ma KSK. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study. J Allergy Clin Immunol. 2024;154(5):1195-203.e3. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"3582_CR34","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/jdv.20724","volume":"39","author":"K Kridin","year":"2025","unstructured":"Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ. The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: a global cohort study. J Eur Acad Dermatol Venereol. 2025;39(12):2069\u201378. https:\/\/doi.org\/10.1111\/jdv.20724.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03582-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03582-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03582-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:05Z","timestamp":1782206525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03582-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03582-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lisa A. Beck is a consultant for AbbVie, Amgen, Apogee, Arcutis, Arena Pharmaceuticals, AstraZeneca, Astria Therapeutics, Bambusa Therapeutics Inc, Belharra Therapeutics, Celldex Therapeutics, Dermavent, Eli Lilly and Company, Escient Pharma, Evommune, Galderma, GlaxoSmithKline, Invea Therapeutics, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Novartis, Numab Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals Inc., ResVitaBio, Inc., Ribon Therapeutics, Sanofi-Aventis\/Genzyme, Sitryx Therapeutics, Stealth BioTherapeutics, TRex Bio, Inc, Triveni Bio, UCB Pharma, UNION Therapeutics, Xencor, and Zai Laboratory; is a Novartis DMC Member; and an investigator for Novartis, Regeneron Pharmaceuticals Inc., and Sanofi. Eric L. Simpson reports being a principal investigator with and in receipt of grants from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron\u00a0Pharmaceuticals Inc., Sanofi-Genzyme, Target, Veriskin; and reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Inmagene Biopharmaceuticals, Innovaderm Reche\/Indero, Janssen, LectureLinx (LLX), LEO\u00a0Pharma, Numab Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, Sitryx Therapeutic. Diamant Tha\u00e7i is a consultant, advisory board member, and\/or investigator, for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, GSK, Janssen-Cilag, LEO Pharma, L'Or\u00e9al, NewBridge, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Samsung, Sanofi, Sun Pharma, Target-RWE, UCB and Vichy. Marjolein de Bruin-Weller: is a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB. Mette Deleuran reports research support\/consulting\/advisory board agreements, travel support, and\/or honoraria for lectures with AbbVie, Almirall, Eli Lilly, Incyte, Kymab, La Roche-Posay, LEO Pharma, Mustela, Numab Therapeutics AG, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and UNION Therapeutics. Yoko Kataoka is or has been a speaker for AbbVie, Maruho, Pfizer, and Sanofi; and a study investigator for AbbVie, Amgen, Eli Lilly, LEO Pharma, Maruho, Otsuka, Pfizer, Sanofi, and Taiho Pharma. Andrew Blauvelt is a speaker for Almirall, Eli Lilly, LEO\u00a0Pharma, Sanofi, and UCB-speaker (received honoraria); a scientific advisor (received honoraria) to AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, LEO\u00a0Pharma, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Rani Therapeutics, Regeneron\u00a0Pharmaceuticals Inc., Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab-; a clinical study investigator (institution has received clinical study funds) with AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO\u00a0Pharma, Merck, Novartis, Pfizer, Regeneron\u00a0Pharmaceuticals Inc., Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. Andreas Wollenberg: has served as an investigator for Beiersdorf, Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; a consultant for AbbVie, Aileens Pharma, Almirall, Anacor Pharmaceuticals, Eli Lilly, Galapagos, Galderma, GSK, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; and has been in receipt of research grants from Beiersdorf, LEO Pharma, and Pierre Fabre.. Lawrence Eichenfield is a consultant with AbbVie, Acrotech, Amgen, Apogee Therapeutics, Arcutis, Attovia, BMS, Castle Biosciences, Dermavant, Eli Lilly, Fort\u00e9, Galderma, Incyte, Janssen, Novartis, Ortho Dematologics, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Takeda, TRex Bio, UCB, and Verrica Pharmaceuticals; and reports study support (to institution) from AbbVie, Castle Biosciences, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and Valeant. Faisal A. Khokhar, Anna Coleman, Yonghao Ma, Elena Avetisova, and Tien V. Nguyen are employees of and shareholders in Regeneron Pharmaceuticals Inc. Michael Van Spall and Annie Zhang are Sanofi employees, and may hold stock and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with the ethical standards of the responsible committees and the Declaration of Helsinki and with the International Council for Harmonisation guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. The protocol was reviewed and approved by institutional review boards\/ethics committees at all centers (Table S4). All patients provided written informed consent before any study procedures began.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}